10MD receives funding from SWElife

Oct 12, 2016

10MD has received funding from the Swedish Innovation Programme for Life Science, SWElife. The funding will primarily be used to support 10MD market access activities.

Ten Medical Design AB (10MD) is a medical technology company committed to providing innovative products to healthcare professionals. In October 2015, 10MD was granted its first patent approval for the attenuating material NAFT. -NAFT is capable of reaching industry standards of x-ray attenuation within the range of 30-150kV, while simuletaneously enabling design of ergonomic and hygienic personal protection equipment. NAFT is expected to reach market in 2017.

- "I am pleased to announce that SWElife has decided to financially support 10MD in this exciting stage taking our first product to market", says Mr Fredrik Gellerstedt, CEO of 10MD.

 

For more information, please contact petra.apell@10md.se.